
Sign up to save your podcasts
Or
Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content:
4.4
456456 ratings
Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content:
131 Listeners
323 Listeners
694 Listeners
37 Listeners
277 Listeners
254 Listeners
3,323 Listeners
8 Listeners
17 Listeners
19 Listeners
14 Listeners
11 Listeners
5 Listeners
7 Listeners
9 Listeners
21 Listeners
87 Listeners
1,084 Listeners
5 Listeners
29 Listeners
15 Listeners
186 Listeners
698 Listeners
513 Listeners
5 Listeners
350 Listeners
244 Listeners
423 Listeners
106 Listeners
21 Listeners
364 Listeners
3 Listeners
162 Listeners